Overview
AI drug design company merged with Recursion in 2024.
Details
Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.
AI drug design company merged with Recursion in 2024. Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.
AI drug design company merged with Recursion in 2024.
Exscientia pioneered AI-designed small molecules entering clinical trials. Now part of Recursion, contributing chemistry AI and a pipeline of AI-designed drugs.
Turn AI reports into shareable sites
Publish reports & dashboards as websites
Make AI-generated reports public, stable, and easy to update — free to start.
Try Revdoku →